Beijing SL Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 002038.SZ

Beijing SL Pharmaceutical Co., Ltd. Operating Income Margin for the year ending December 31, 2023: 46.93%

Beijing SL Pharmaceutical Co., Ltd. Operating Income Margin is 46.93% for the year ending December 31, 2023, a 87.15% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Beijing SL Pharmaceutical Co., Ltd. Operating Income Margin for the year ending December 31, 2022 was 25.07%, a -33.43% change year over year.
Beijing SL Pharmaceutical Co., Ltd. Operating Income Margin for the year ending December 31, 2021 was 37.66%, a 1.51% change year over year.
Beijing SL Pharmaceutical Co., Ltd. Operating Income Margin for the year ending December 31, 2020 was 37.11%, a 34.27% change year over year.
Beijing SL Pharmaceutical Co., Ltd. Operating Income Margin for the year ending December 31, 2019 was 27.63%, a -12.13% change year over year.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

Shenzhen Stock Exchange: 002038.SZ

Beijing SL Pharmaceutical Co., Ltd.

CEO	Dr. Mingbo Xu Ph.D.
IPO Date	Sept. 9, 2004
Location	China
Headquarters	Building 1, Bitongyuan
Employees	856
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, produces, and markets genetic engineering and related drugs in the People's Republic of China and internationally. The company's finished formulations includes temozolomide; arsenic trioxide; lenalidomide; docetaxel; paclitaxel; filgrastim Recombinant human granulocyte colony-stimulating factor; recombinant human interleukin-11; recombinant human interleukin-2; thymopentin; vinorelbine bitartrate; hydroxyl-camptothecine; nimustine hydrochloride; asparaginase; PEG L-asparaginase; calcium foliate; recombinant human basic fibroblast growth factor; ciclosporin; mycophenolate mofetil dispersible; ornidazole; adefovir dipivoxil; levofloxacin hydrochloride; azithromycin; ribavirin; tenofovir disoproxil fumarate; valacylovir hydrochloride; lysozyme; stavudine; tropisetron hydrochloride; granisetron hydrochloride; omeprazole; ademetionine 1,4-butanedisulfonate; glutathione; enoxaparin sodium; coenzyme complex; ginkgo biloba extract; simvastatin; telmisartan; naftopidil; nicergoline; zaleplon; cytidine disodium triphosphate; febuxostat; risedronate sodium; loratadine dispersible; somatostatin; octreotide acetate; calcitonin (salmon); paracetamol and tramadol hydrochloride; and etodolac. It also offers active pharmaceutical ingredients. The company was formerly known as Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd and changed its name to Beijing SL Pharmaceutical Co., Ltd. in 1998. Beijing SL Pharmaceutical Co., Ltd. was founded in 1994 and is based in Beijing, the People's Republic of China.

Key trends

Past 5 years